Valuation: Viking Therapeutics, Inc.

Market Cap 4.22B 3.69B 3.41B 3.14B 5.92B 407B 6.05B 40.7B 16.01B 199B 15.86B 15.51B 686B P/E 2026 *
-7.57x
P/E 2027 * -7.86x
Enterprise Value 3.77B 3.3B 3.04B 2.8B 5.29B 363B 5.4B 36.36B 14.3B 178B 14.17B 13.86B 612B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.21%
Yield 2026 *
-
Yield 2027 * -
1 day+0.84%
1 week-5.51%
Current month-5.87%
1 month+21.23%
3 months+4.32%
6 months+9.55%
Current year+4.38%
1 week 35.29
Extreme 35.29
38.7
1 month 30.16
Extreme 30.1614
42.79
Current year 25.77
Extreme 25.77
42.79
1 year 22.96
Extreme 22.959
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 2012-09-23
Director of Finance/CFO 55 2021-01-03
Chief Tech/Sci/R&D Officer 57 2026-06-10
Director TitleAgeSince
Chairman 68 2015-04-30
Chairman 60 2012-09-23
Director/Board Member 53 2014-04-30
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Free

Chief Technology Officer

190,000 0.1636%
3/10/26 Buy

Executive/Senior Manager

4,475 0.0039%
1/12/26 Free

Executive/Senior Manager

180,000 0.1592%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-5.51%+14.50%+137.21% 4.22B
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+1.04%-6.03%+4.29%+424.83% 23.29B
-0.15%+0.02%-17.59%-14.64% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
-0.05%-1.43%+24.11%+190.20% 14B
Average -2.43%-2.29%+41.01%+180.70% 24.47B
Weighted average by Cap. -2.86%-2.36%+42.79%+144.96%

Financials

2026 *2027 *
Net sales - -
Net income -563M -492M -454M -418M -789M -54.22B -806M -5.43B -2.13B -26.55B -2.11B -2.07B -91.41B -587M -513M -474M -437M -823M -56.57B -841M -5.66B -2.23B -27.7B -2.21B -2.16B -95.37B
Net Debt -450M -394M -363M -335M -631M -43.37B -645M -4.34B -1.71B -21.24B -1.69B -1.65B -73.13B -523M -457M -422M -389M -733M -50.41B -750M -5.05B -1.98B -24.69B -1.97B -1.92B -84.99B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
59
Date Price Change Volume
26-07-17 US$36.77 +1.09% 742,140
26-07-16 US$36.37 -3.81% 1,529,156
26-07-15 US$37.81 -0.42% 1,228,470
26-07-14 US$37.97 -0.39% 1,341,034
26-07-13 US$38.12 -1.90% 2,006,678
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
36.37USD
Average target price
92.58USD
Spread / Average Target
+154.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock